Literature DB >> 20129712

[Clinical characteristics of patients under treatment for osteoporosis in a Primary Care Centre. Who do we treat?].

Ricardo de Felipe1, Cristina Cáceres, Marta Cimas, Gemma Dávila, Silvia Fernández, Tania Ruiz.   

Abstract

OBJECTIVES: To find out the clinical and demographic features of patients in treatment for osteoporosis, look for risk factors for osteoporosis and bone fractures, and assess whether treatment is indicated.
DESIGN: Descriptive study of a series of cases. LOCATION: Primary Care Centre, Madrid. PARTICIPANTS: 216 patients on treatment for osteoporosis during 2007. PRINCIPAL MEASURES: Sociodemographic variables, osteoporosis risk factors, risk of falling, prescription and treatment related information. To evaluate if treatment is indicated we have used principal medical guidelines.
RESULTS: Most of our patients were Caucasian women with a mean age of 66.14 years. A total of 39.5% had suffered an osteoporotic fracture and 16.12% had family history of osteoporotic fracture. The majority of our registers,73.15%, do not report information on Dual-Energy X-ray Absorptiometry (DEXA), and 73.13% do not make any reference to bone mineral density. Risk factors are not recorded in most of the clinical histories. Only 51.85% of the treatments were well indicated, and 44% of them began at a primary health care centre.
CONCLUSIONS: Nearly 50% of treatments are not well indicated and a high percentage of our clinical histories do not record risk factors correctly. We should improve our clinical histories, as we are responsible for identifying, studying, evaluating, treating and controlling the progress of osteoporosis.
Copyright © 2009 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20129712      PMCID: PMC7024519          DOI: 10.1016/j.aprim.2009.10.022

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  4 in total

1.  Bone mineral density and androgen levels in elderly males.

Authors:  A Rapado; F Hawkins; L Sobrinho; M Díaz-Curiel; A Galvao-Telles; S Arver; J Melo Gomes; N Mazer; J Garcia e Costa; C Horcajada; E López-Gavilanes; M Mascarenhas; K Papapietro; M B López Alvarez; M C Pereira; G Martinez; I Valverde; J J García; J J Carballal; I García
Journal:  Calcif Tissue Int       Date:  1999-12       Impact factor: 4.333

2.  Risk factors for vertebral deformities in men: relationship to number of vertebral deformities. European Vertebral Osteoporosis Study Group.

Authors:  A A Ismail; T W O'Neill; C Cooper; A J Silman
Journal:  J Bone Miner Res       Date:  2000-02       Impact factor: 6.741

Review 3.  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

Authors: 
Journal:  Arthritis Rheum       Date:  2001-07

4.  Prevalence and incidence of vertebral deformities.

Authors:  L J Melton; A W Lane; C Cooper; R Eastell; W M O'Fallon; B L Riggs
Journal:  Osteoporos Int       Date:  1993-05       Impact factor: 4.507

  4 in total
  11 in total

1.  [What can we do about the long-term use of bisphosphonates? Fractures and atrial fibrillation].

Authors:  Gemma Rodríguez Palomar; M Àngels Pellicer Jacomet
Journal:  Aten Primaria       Date:  2011-06-29       Impact factor: 1.137

2.  Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study.

Authors:  L H Martín Arias; C Treceño; P García-Ortega; J Rodríguez-Paredes; A Escudero; M Sáinz; I Salado; V Velasco; A Carvajal
Journal:  Eur J Clin Pharmacol       Date:  2012-07-21       Impact factor: 2.953

3.  Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort.

Authors:  J Sanfélix-Genovés; G Sanfélix-Gimeno; S Peiró; I Hurtado; C Fluixà; A Fuertes; J C Campos; V Giner; C Baixauli
Journal:  Osteoporos Int       Date:  2012-05-23       Impact factor: 4.507

4.  Regional variability in changes in the incidence of hip fracture in the Spanish population (2000-2012).

Authors:  I Etxebarria-Foronda; A Arrospide; M Soto-Gordoa; J R Caeiro; L C Abecia; J Mar
Journal:  Osteoporos Int       Date:  2015-01-09       Impact factor: 4.507

5.  Criteria for the prescription of oral bisphosphonates for the treatment of osteoporosis in a series of women referred for tooth extraction.

Authors:  Márcio Diniz-Freitas; Javier Fernández-Feijoo; Paula Fernández-Montenegro; Antonio González-Mosquera; Emma Vázquez-García; Pedro Diz-Dios
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2012-07-01

6.  Adherence to and appropriateness of anti-osteoporotic treatments in patients aged 50 and over in the Valencia Region (Spain). The ESOSVAL-AD study.

Authors:  Gabriel Sanfélix-Gimeno; José Sanfélix-Genovés; Salvador Peiró; Isabel Hurtado; José Luis Trillo; Ruth Usó; Vicente Giner Ruiz; Manuel Pascual de la Torre; Inmaculada Ferreros
Journal:  BMC Musculoskelet Disord       Date:  2011-08-03       Impact factor: 2.362

7.  Overuse and Underuse of Antiosteoporotic Treatments According to Highly Influential Osteoporosis Guidelines: A Population-Based Cross-Sectional Study in Spain.

Authors:  Gabriel Sanfélix-Gimeno; Isabel Hurtado; José Sanfélix-Genovés; Cristóbal Baixauli-Pérez; Clara L Rodríguez-Bernal; Salvador Peiró
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

8.  Variation in Antiosteoporotic Drug Prescribing and Spending Across Spain. A Population-Based Ecological Cross-Sectional Study.

Authors:  Gabriel Sanfélix-Gimeno; Julián Librero-López; Gracia Modroño-Riaño; Salvador Peiró; Clara L Rodríguez-Bernal
Journal:  Front Pharmacol       Date:  2018-04-13       Impact factor: 5.810

9.  Variations in osteoporosis medication utilization. A population-based ecological cross-sectional study in the region of Valencia, Spain.

Authors:  Gabriel Sanfélix-Gimeno; María-Lirios Juliá-Sanchis; Julián Librero; Salvador Peiró; Aníbal García-Sempere
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

10.  Assessment of the antiosteoporotic treatment initiation: A retrospective observational study in Greece.

Authors:  Stavroula Rizou; Leon Aravantinos; Aristofanis Paganas; Michael Ballas; George P Lyritis
Journal:  J Frailty Sarcopenia Falls       Date:  2017-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.